BridgeBio Pharma (BBIO) Equity Ratio: 2019-2025
Historic Equity Ratio for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -1.94.
- BridgeBio Pharma's Equity Ratio fell 5.63% to -1.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -1.94, marking a year-over-year decrease of 5.63%. This contributed to the annual value of -1.60 for FY2024, which is 35.58% up from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's Equity Ratio is -1.94, which was down 17.00% from -1.66 recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's Equity Ratio ranged from a high of -0.36 in Q1 2021 and a low of -2.68 during Q2 2023.
- Its 3-year average for Equity Ratio is -1.85, with a median of -1.83 in 2024.
- In the last 5 years, BridgeBio Pharma's Equity Ratio slumped by 666.85% in 2021 and then spiked by 49.19% in 2024.
- BridgeBio Pharma's Equity Ratio (Quarterly) stood at -0.86 in 2021, then tumbled by 133.12% to -2.00 in 2022, then dropped by 24.20% to -2.48 in 2023, then skyrocketed by 35.58% to -1.60 in 2024, then fell by 5.63% to -1.94 in 2025.
- Its last three reported values are -1.94 in Q3 2025, -1.66 for Q2 2025, and -1.87 during Q1 2025.